8-K: NKGen Biotech Amends Forward Purchase Agreement with Polar Multi-Strategy Master Fund

NKGen Biotech has amended its forward purchase agreement with Polar Multi-Strategy Master Fund, extending the valuation date and modifying key terms.

Summary

• NKGen Biotech amended its forward purchase agreement with Polar Multi-Strategy Master Fund on July 29, 2024.
• The amendment extends the valuation date to December 31, 2024, or an earlier date at the seller's discretion following certain trigger events.
• The reset price will be adjusted weekly based on the lowest of 90% of the prior week's VWAP, the current reset price, or the initial price.
• A prepayment shortfall of 0.50% of recycled shares multiplied by the initial price is included, with an additional $500,000 cash payment at NKGen's request.
• The seller can sell shares to cover the initial shortfall and 120% of the future shortfall, provided the sales are at or above the reset price.
• The seller has the option to terminate the transaction in whole or in part by providing written notice.
• NKGen is restricted from issuing more than $20 million of shares or convertible securities for 30 days after the prepayment date without the seller's consent.
• If a shortfall variance occurs, NKGen can either pay cash or issue additional shares to the seller.
• NKGen will issue 80,000 shares to the seller, plus an additional 500,000 shares conditional on payment of the future shortfall.
• Upon the seller's request, NKGen will instruct the escrow agent to remit all escrowed funds to the seller.

Sentiment

Score: 4

Explanation: The amendment introduces potentially dilutive terms and immediate costs, which are negative for existing shareholders. The company is also seeking additional finance which may not be available or may be on unfavorable terms. The extension of the valuation date is a minor positive.

Positives

• The extension of the valuation date provides NKGen with more time before the transaction is finalized.
• The ability to adjust the reset price weekly could result in a lower price for the seller, potentially benefiting NKGen.
• The release of escrow funds provides immediate liquidity to the seller.

Negatives

• The potential for a lower reset price could result in the seller selling shares at a lower value.
• The prepayment shortfall and additional cash payment represent an immediate cost to NKGen.
• The issuance of additional shares dilutes existing shareholders' equity.
• The restriction on issuing more than $20 million of shares for 30 days could limit NKGen's financial flexibility.

Risks

• The weekly reset price adjustment could lead to significant fluctuations in the share price.
• The potential for shortfall variance could result in further dilution of shares or cash payments.
• The seller's ability to sell shares at any time could create downward pressure on the stock price.
• The company is seeking additional finance which may not be available or may be on unfavorable terms.

Future Outlook

The company continues to seek additional finance on terms consistent with prior financings.

Management Comments

• The company is seeking additional finance on terms consistent with the company's prior financings, or otherwise, previously disclosed in the company's current reports on Form 8-K.

Industry Context

This amendment is a specific financial transaction for NKGen and does not directly reflect broader industry trends, but it does highlight the ongoing need for biotech companies to secure funding.

Comparison to Industry Standards

• Forward purchase agreements are a common financing tool for companies, particularly those that have recently completed a SPAC merger.
• The terms of this agreement, such as the reset price and shortfall provisions, are specific to the agreement between NKGen and Polar Multi-Strategy Master Fund.
• Comparable companies may have similar agreements, but the specific terms would vary based on their individual circumstances and negotiations.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of additional shares.
• The seller benefits from the extended valuation date and the potential for share sales.
• The company's financial flexibility may be limited by the restrictions on issuing new shares.

Next Steps

• NKGen will need to pay the prepayment shortfall, including the additional $500,000 cash payment.
• NKGen will need to issue the additional 580,000 shares to the seller.
• NKGen will need to instruct the escrow agent to remit all escrowed funds to the seller.
• NKGen will continue to seek additional finance.

Key Dates

Keywords

Forward Purchase Agreement, Valuation Date, Reset Price, Prepayment Shortfall, Share Consideration, Escrow Account, Dilutive Offering, Shortfall Sales, Optional Early Termination, VWAP Trigger Event